retatrutide phase 2 trial obesity triple agonist meets primary endpoints in two III trials, reporting up to 22.6% weight loss – touchENDOCRINOLOGY triple hormone receptor agonist retatrutide
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26





























